

The ACME Laboratories Limited
Interim First Quarter Un-Audited Financial Statements
For the period ended 30 September 2024

The ACME Laboratories Limited
Statement of Financial Position (Un-Audited)
As at 30 September 2024

		Amount in Taka	
ASSETS	NOTES	As at 30-09-2024	As at 30-06-2024
Non-Current Assets :		31,959,666,947	31,759,350,787
Property, Plant and Equipment	3	31,862,599,258	31,658,701,709
Right-of-Use Assets		63,252,339	70,446,949
Investment in Securities		33,815,350	30,202,129
Current Assets:		23,819,347,959	23,862,813,599
Inventories	4	8,739,813,130	8,549,599,532
Trade Receivable	5	3,382,919,346	3,259,015,148
Other Receivable		30,739,687	20,132,305
Advance, Deposits & Pre-Payments	6	3,486,481,468	3,513,092,438
Advance Income Tax		3,508,462,597	3,390,754,893
Material In Transit		2,858,716,894	3,321,884,425
Term Deposit		97,120,287	56,320,480
Cash and Cash Equivalents	7	1,715,094,550	1,752,014,378
TOTAL ASSETS		55,779,014,906	55,622,164,386
EQUITY AND LIABILITIES			
Shareholders' Equity :		25,607,902,712	25,051,830,131
Share Capital	8	2,116,017,000	2,116,017,000
Share Premium		5,127,599,728	5,127,599,728
Revaluation Surplus		4,960,088,147	4,971,562,521
Gain/(Loss) on Marketable Securities (Unrealized)		6,879,143	3,627,244
Tax Holiday Reserve		179,464,241	179,464,241
Retained Earnings		13,217,854,453	12,653,559,397
Non Current Liabilities:		8,896,280,015	9,039,412,648
Long Term Loan- Net off Current Maturity		6,564,478,189	6,753,319,650
Long Term Lease Liability		41,979,449	44,870,025
Provision For Gratuity		1,540,129,207	1,450,653,876
Deferred Tax Liability		749,693,170	790,569,097
Current Liabilities:		21,274,832,179	21,530,921,607
Loans & Overdrafts		14,569,609,832	15,052,662,241
Current Maturity of Long Term Loans		2,096,086,349	2,115,351,375
Trade Payable		572,422,673	603,668,457
Provision for Income Tax		3,239,615,952	3,022,082,571
Current Lease Liability		19,399,363	21,488,161
Liability for Expenses and Others		773,869,955	711,837,103
Dividend Payable	19	3,828,055	3,831,699
Unclaimed Dividend Account		-	-
TOTAL EQUITY AND LIABILITIES		55,779,014,906	55,622,164,386
Net Asset Value Per Share (NAVPS)	9	121.02	118.39

Sd/-
Masudur Rahman Bhuiyan FCS
Company Secretary

Sd/-
Kazi Mohammed Badruddin FCMA, FCA
ED & CFO

Sd/-
Sabrina Juned
Director

Sd/-
Mizanur Rahman Sinha
Managing Director

Sd/-
Nagina Afzal Sinha
Chairman

The ACME Laboratories Limited

Statement of Profit or Loss and Other Comprehensive Income (Un-Audited)
For the period ended 30 September 2024

PARTICULARS	Notes	Amount in Taka	
		July'24 to September'24	July'23 to September'23
Revenue		8,340,543,888	7,920,009,490
Less: Cost of Goods Sold	11	4,884,610,056	4,695,174,660
Gross Profit/(Loss)		3,455,933,832	3,224,834,830
Add: Other Income/ (Loss)		(26,925,406)	(108,980,524)
		3,429,008,426	3,115,854,306
Less: Selling, Marketing and Distribution Expenses	12	1,622,236,860	1,409,377,395
		1,806,771,566	1,706,476,911
Less: Administrative Expenses	13	281,969,178	249,511,053
		1,524,802,388	1,456,965,858
Less: Financial Expenses		759,229,733	578,602,364
Profit Before Contribution to WPPF and WWF		765,572,655	878,363,494
Less: Contribution to WPPF and WWF		36,455,841	41,826,833
Net Profit Before Tax		729,116,814	836,536,661
Less: Current Tax Expenses		217,533,381	219,813,670
Less: Deferred Tax (Income)/Expenses	15	(41,237,249)	(41,848,635)
Net Profit After Tax		552,820,682	658,571,626
Other Comprehensive Income			
Gain/(Loss) on Marketable Securities (Unrealized)		3,613,221	163,851
Total Comprehensive Income for the period		556,433,903	658,735,477
Earnings Per Share (on the Equity share of Tk. 10 each)	16	2.61	3.11

Sd/-
Masudur Rahman Bhuiyan FCS
Company Secretary

Sd/-
Kazi Mohammed Badruddin FCMA, FCA
ED & CFO

Sd/-
Sabrina Juned
Director

Sd/-
Mizanur Rahman Sinha
Managing Director

Sd/-
Nagina Afzal Sinha
Chairman

The ACME Laboratories Limited

Statement of Changes in Equity (Un-Audited)
For the period ended 30 September 2024

(Amount in Taka)

Particulars	Share Capital	Share Premium	Revaluation Surplus	Gain/(loss) on Marketable Securities (Unrealized)	Tax Holiday Reserve	Retained Earnings	Total
Balance as at July 01, 2024	2,116,017,000	5,127,599,728	4,971,562,521	3,627,244	179,464,241	12,653,559,397	25,051,830,131
Net Profit after Tax for the period ended 30 September 2024	-	-	-	-	-	552,820,682	552,820,682
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	3,613,221	-	-	3,613,221
Adjustment for Depreciation on Revaluation Surplus & Others	-	-	(11,474,374)	-	-	11,474,374	-
Deferred Tax on Unrealized Gain/Losses on Investment in Securities	-	-	-	(361,322)	-	-	(361,322)
Balance as at 30 September 2024	2,116,017,000	5,127,599,728	4,960,088,147	6,879,143	179,464,241	13,217,854,453	25,607,902,712
Balance as at 30 September 2023	2,116,017,000	5,127,599,728	5,005,899,067	5,093,859	179,464,241	11,519,898,779	23,953,972,674

Sd/-
Masudur Rahman Bhuiyan FCS
Company Secretary

Sd/-
Kazi Mohammed Badruddin FCMA, FCA
ED & CFO

Sd/-
Sabrina Juned
Director

Sd/-
Mizanur Rahman Sinha
Managing Director

Sd/-
Nagina Afzal Sinha
Chairman

The ACME Laboratories Limited

Statement of Cash Flows (Un-Audited)

For the year period 30 September 2024

PARTICULARS

Amount in Taka

	Notes	July'24 to September'24	July'23 to September'23
Cash Flows From Operating Activities:			
Collection from Sales and others		8,179,005,125	7,779,809,396
Payment to Suppliers & Others		(5,939,399,425)	(6,407,364,081)
Payment to WPPF and WWF		-	(6,747,150)
Cash generated from operation		2,239,605,700	1,365,698,165
Financial Expenses		(759,229,733)	(578,602,364)
Income Tax Paid		(117,707,704)	(166,715,082)
A. Net Cash Generated From Operating Activities		1,362,668,263	620,380,719
Cash Flows From Investing Activities:			
Acquisition of Property, Plant & Equipments		(662,748,148)	(850,604,625)
Term Deposit		(40,799,807)	(655,799)
Dividend received from Investment in Marketable Securities		101,777	46,623
B. Net Cash Used in Investing Activities		(703,446,178)	(851,213,801)
Cash Flows From Financing Activities:			
Dividend Paid		(3,644)	(2,441,277)
Principal Portion payment of Lease Liability		(4,979,373)	(5,085,791)
Net Increase / (Decrease) in Loans and Overdrafts		(483,052,409)	670,140,853
Net Increase / (Decrease) in Long Term Borrowings		(208,106,487)	347,769,206
C. Net Cash Generated/(Used) From Financing Activities		(696,141,913)	1,010,382,991
Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		(36,919,828)	779,549,910
Cash and Cash Equivalents at the Opening		1,752,014,378	1,455,376,682
Cash and Cash Equivalents at the Closing		1,715,094,550	2,234,926,592
Net Operating Cash Flow Per Equity Share (NOCFPS)	17	6.44	2.93

Sd/-
Masudur Rahman Bhuiyan FCS
Company Secretary

Sd/-
Kazi Mohammed Badruddin FCMA, FCA
ED & CFO

Sd/-
Sabrina Juned
Director

Sd/-
Mizanur Rahman Sinha
Managing Director

Sd/-
Nagina Afzal Sinha
Chairman

The ACME Laboratories Limited

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 30 September 2024

1 Reporting Entity

The ACME Laboratories Ltd. was founded in the year 1954 as a Proprietorship Firm and it was converted into a Private Limited Company on 17th March 1976 vide registration no. C-4745/163 of 1975-76 under the Companies Act-1913. Further, it was converted into a public limited company on 30th November 2011.

2 Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Annual Financial Statements for the Year ended 30 June 2024, as they provide an update of previously reported information.

These financial statements have been prepared in accordance with Framework, applicable International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs), Companies Act 1994, Bangladesh Securities and Exchange Rules 1987 and other relevant laws and regulations applicable in Bangladesh. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Previous period's figures have been regrouped/reclassified wherever considered necessary to confirm to current Period's presentation. Figures have been rounded off to the nearest taka, as the currency represented in these financial statements.

3 Property Plant and Equipment

	Amount in Taka	
	As at 30-09-2024	As at 30-06-2024
Opening Balance	43,498,987,590	39,450,188,902
Add: Addition (Net off Adjustment) during the Period	641,202,252	4,048,798,688
Less: Accumulated Depreciation (Net off Adjustment)	12,277,590,584	11,840,285,881
Carrying Value	31,862,599,258	31,658,701,709

4 Inventories

This consists of as follows:

Raw Materials	3,620,367,929	3,844,388,375
Packing Materials	1,490,897,880	1,344,622,839
Work-in-Process	993,786,606	1,067,010,877
Finished Goods	1,951,682,800	1,663,995,746
Printing & Stationery	17,186,628	15,076,532
Spare, Accessories & Others	665,891,287	614,505,163
Total	8,739,813,130	8,549,599,532

5 Trade Receivable

Domestic	2,945,600,523	2,838,098,179
Exports	418,340,549	390,649,227
	3,363,941,072	3,228,747,406
Foreign exchange Unrealized Gain	18,978,274	30,267,742
	3,382,919,346	3,259,015,148

The ACME Laboratories Limited

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 30 September 2024

		Amount in Taka	
		As at 30-09-2024	As at 30-06-2024
6 Advances, Deposits and Prepayment			
Advances		2,437,656,853	2,336,159,729
Deposit		1,039,635,122	1,159,570,617
Prepayments		9,189,493	17,362,092
		3,486,481,468	3,513,092,438
7 Cash and Cash Equivalents			
This is made up as follows :			
Cash in Hand		896,214,445	887,761,342
Cash at Bank		816,789,498	862,442,856
Cash at BO Account		2,090,607	1,810,180
		1,715,094,550	1,752,014,378
8 Share Capital :			
This is arrived at as follows :			
a) Authorized Capital : Tk 5,000,000,000			
500,000,000 Ordinary share of Tk. 10 each		5,000,000,000	5,000,000,000
b) Issued, Subscribed and Paid - up Capital:			
211,601,700 Ordinary Shares @ Tk. 10 each		2,116,017,000	2,116,017,000
		2,116,017,000	2,116,017,000
c) Movement in Number of Ordinary Shares is as under:			
Opening Balance		211,601,700	211,601,700
Add: Issued during the Period		-	-
Closing Balance		211,601,700	211,601,700
9 Calculation of Net Asset Value (NAV) per ordinary share of Tk. 10 each:			
A Total Equity of the Company		25,607,902,712	25,051,830,131
B Total Number of outstanding ordinary share at the end of the period		211,601,700	211,601,700
C Net Asset Value per Ordinary Share (A/B) rounded of upto two decimal places		121.02	118.39

The ACME Laboratories Limited

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 30 September 2024

10 History of allotment of Shares by the Company:

Date of Allotment	Particulars of allotment	Number of ordinary shares allotted	Face Value (Tk)	Amount of Share Capital(Tk.)
17.03.1976	First (Subscription to the Memorandum and Articles of Association at the time of Incorporation)	600	10	6,000
16.05.1976	Second	29,500	10	295,000
10.08.1989	Third	300,000	10	3,000,000
29.11.2006	Fourth	9,669,900	10	96,699,000
05.05.2011	Fifth	106,000,000	10	1,060,000,000
20.05.2013	Sixth	39,631,100	10	396,311,000
26.11.2013	Seventh	5,970,600	10	59,706,000
15.05.2016	Eighth	50,000,000	10	500,000,000
		211,601,700		2,116,017,000

Amount in Taka

July 24 to September 24 July 23 to September 23

11 Cost of Goods Sold

Material Consumption during the period	3,755,283,255	3,540,393,103
Factory Overhead	1,417,013,855	1,166,237,221
Cost of Production	5,172,297,110	4,706,630,324
Purchase of Finished Goods	-	-
Opening Stock of Finished Goods	1,663,995,746	1,384,387,903
Finished Goods Available	6,836,292,856	6,091,018,227
Closing Stock of Finished Goods	(1,951,682,800)	(1,395,843,567)
Cost of Goods Sold	4,884,610,056	4,695,174,660

12 Selling, Marketing and Distribution Expenses

Salary, Daily Wages and Other Allowances	1,166,593,814	973,070,953
Depreciation and others	455,643,046	436,306,442
	1,622,236,860	1,409,377,395

Selling, Marketing and Distribution expenses has been rearranged due to transfer of product registration cost from Administrative expenses to selling, Marketing and Distribution Expenses. However Combining of total expenditure of Selling, Marketing and Distribution expenses and Administrative expenses are same and does not affect the earnings of the company both for the current year and previous year.

13 Administrative Expenses

Salary, Daily Wages and Other Allowances	167,182,828	148,975,099
Depreciation and others	114,786,350	100,535,954
	281,969,178	249,511,053

The ACME Laboratories Limited

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 30 September 2024

		Amount in Taka	
		July 24 to September 24	July 23 to September 23
14 Reconciliation of Effective Tax Rate			
Net Profit before Tax		729,116,814	836,536,661
Current Tax Expenses		217,533,381	219,813,670
Deferred Tax Expenses/(Income)		(41,237,249)	(41,848,634)
		176,296,132	177,965,036
Effective Tax Rate		24.18%	21.27%
15 Deffered Tax Expenses/(Income):			
Property, Plant and Equipment- Difference in book value & Tax base		(118,584,439)	(137,515,223)
Temporary Difference of Gratuity		(89,475,331)	(84,196,194)
Temporary Difference of Lease Liability & ROU Assets		1,873,527	12,468,244
Total Taxable/ (Deductible) Difference		(206,186,243)	(209,243,173)
Deffered Tax Expenses/ (Income) during the period		(41,237,249)	(41,848,635)
16 Basic/Diluted Earning Per Share (EPS):			
Net Profit After Tax		552,820,682	658,571,626
Weighted average number of shares outstanding during the period		211,601,700	211,601,700
Basic Earnings Per Share		2.61	3.11
17 Net Operating Cash Flows Per Share:			
Net cash generated from operating activities		1,362,668,263	620,380,719
Weighted average number of shares outstanding during the period		211,601,700	211,601,700
Net Operating Cash Flows Per Share*		6.44	2.93

*Net operating Cash Flows per share has been increased due to increase in sales collection and less payment to supplier and payment against Letter of Credit (L/C) compared to same period of previous year

The ACME Laboratories Limited

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 30 September 2024

18 Reconciliation of Net Income or Net Profit with Cash Flows from Operating Activities-Indirect Method

	July 24 to September 24	July 23 to September 23
Net Profit after Tax	556,433,903	658,571,626
Add: Non Cash Items	617,182,223	303,361,487
Less: Net Increase/Decrease in Current Asset	(68,891,515)	800,434,818
Add: Net Increase/Decrease in Current Liabilities	120,160,622	458,882,424
Net cash generated from operating activities-Direct Method	1,362,668,263	620,380,719

19 Dividend Payable

As per BSEC Directive no.BSEC/CMRRCD/2021-386/03 dated 14th January, 2021 Dividend payable not more than 03 years are as follows:

S.L	Financial Year	Dividend	% of Dividend	No. of BO	Date of AGM	Dividend Payable (Tk.)
1	2020-2021	Cash	25%	1,281	26.12.2021	1,601,596
2	2021-2022	Cash	30%	1,197	20.12.2022	1,338,066
3	2022-2023	Cash	33%	911	18.12.2023	888,392
Dividend Payable as at 30 September 2024						3,828,055

Sd/-
Masudur Rahman Bhuiyan FCS
Company Secretary

Sd/-
Kazi Mohammed Badruddin FCMA, FCA
ED & CFO

Sd/-
Sabrina Juned
Director

Sd/-
Mizanur Rahman Sinha
Managing Director

Sd/-
Nagina Afzal Sinha
Chairman